Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts ...

Executives at the laboratory companies said they expect the effects on testing services from the Republicans’ tax and ...

(Reuters) -Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for its muscular gene therapy soothes immediate concerns about ...

Q1 2026 Management View CEO Sanjay Mirchandani reported a strong start to the fiscal year, highlighting that "total ARR grew ...